Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG2918 in Relapsed/Refractory Multiple Myeloma
NCT07454187Phase 2Recruiting
- Sponsor
- Shangjian Bio
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SG2918 in multiple myeloma (MM), sponsored by Shangjian Bio. Started Apr 2026; status: recruiting.
02
Drugs
SG2918
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07454187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454187.